Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.

Abstract: A new transmutation assembly permits an efficient transmutation of a long-lived radioactive material (long-lived FP nuclides such as technetium-99 or iodine-129) which was produced in the nuclear reactor. Wire-type members of a long-lived radioactive material comprised of metals, alloys or compounds including long-lived FP nuclides are surrounded by a moderator material and installed in cladding tubes to form FP pins. The FP pins, and nothing else, are housed in a wrapper tube to form a transmutation assembly. The wire-type members can be replaced by thin ring-type members. The transmutation assemblies can be selectively and at least partly loaded into a core region, a blanket region or a shield region of a reactor core in a fast reactor. From a viewpoint of reducing the influence on the reactor core characteristics, it is optimal to load the transmutation assemblies into the blanket region.

Abstract: Neptunium of minor actinide nuclides separated from spent fuel is added to fuel of reactor cores (inner reactor cores and/or outer reactor cores) of a fast reactor and americium of the separated minor actinide nuclides and rare earth elements are added to either or both of radial and axial blankets of the fast reactor for burning. Thus, the minor actinide nuclides with long half-lives can be burnt with the fast reactor core with the minimized effects of the rare earth elements. For a burner reactor, americium and rare earth elements may be added to shields for burning. Curium may be added together with americium and rare earth elements. Neptunium is added in amount of 2% to 5% by weight based on the weight of the fuel and the rare earth elements are added in an amount of 50% by weight or less based on the weight of the fuel. A Purex process is used to separate neptunium and a Truex process is used to separate americium and curium.

Abstract: The invention provides a heterogeneously loaded type of fast reactor core in which a reduced number of target fuel assemblies containing minor actinide nuclides are heterogeneously dispersed and loaded. A wrapper tube for each of the target fuel assemblies is of the same shape and size as a hexagonal wrapper tube for an ordinary core fuel assembly. Each of target fuel rods within the wrapper tube contains 20 to 50% of minor actinide nuclides, and has a diameter more reduced than that of an ordinary core fuel rod. The number of the ordinary core fuel rods loaded in the ordinary core fuel assembly is 271 while the number of the target fuel rods loaded in the target fuel assembly is 331 or 397. Thirty to 50 such target fuel assemblies are heterogeneously dispersed and loaded in the fast reactor core.

Abstract: A nutritional liquid emulsion for transfusion comprising of a mixture of fatty acid esters containing 20-22 carbon atoms which are contained in a purified fish oil selected from the group consisting of sardine oil, cod oil, squid oil, mackerel oil or Euphauciacea oil, of a purified soybean or safflower oil, of purified yolk lecithin or soybean lecithin and the balance water. Said nutritional liquid emulsion for transfusion is well balanced in fatty acid composition and is nutritionally valuable and also possesses antithorombotic activity and antiarteriosclerotic activity.

Abstract: Novel amide derivatives are disclosed. As examples of said amide derivatives are mentioned 1-[2-[5-(3-methoxy-4-ethoxycarbonyloxyphenyl)-2,4-pentadienoyl]-aminoethyl ]-4-benzhydroxypiperidine, 1-[2-[3-(3-methoxy-4-ethoxycarbonyloxyphenyl)-2-propenoyl]-4-benzhydroxypi peridine, 1-[3-[-(3-methoxy-4-ethoxycarbonyloxyphenyl)-2,4-pentadienoyl]aminopropyl] -4-benzhydrylpiperazine and the like. These amide derivatives are useful as antiallergic agents.

Abstract: Novel amide derivatives are disclosed. As examples of said amide derivatives are mentioned 1-[2-(5-(3-methoxy-4-benzyloxyphenyl)-2,4-pentadienoyl)aminoethyl]-4-diphe nylmethoxypiperidine, 1-[2-(5-(3-methoxy-4-pentadienoyl)aminoethyl]-4-diphenylmethoxypiperidine and 1-[2-(5-(3-methoxy-4-ethoxymethoxyphenyl)-2,4-pentadienoyl)aminoethyl]-4-d iphenylmethoxypiperidine. These amide derivatives are useful as antiallergic agents.

Abstract: Novel amide derivatives are disclosed. As examples of said amide derivatives are mentioned N-cyclohexyl-N-methyl-(2-(3-(3-methoxy-4-hydroxyphenyl)-2-(propenoylamino) -3, 5-dibromobenzyl)amine and N-cyclohexyl-N-methyl-(2-(5-(3-methoxy-4-hydroxyphenyl)-2,4-pentadienoylam ino )-3,5-dibromobenzyl)amine. These amide derivatives have a 5-lipoxygenase inhibitory activity and are useful as an antiallergic agent.

Abstract: Novel amide derivatives are disclosed. As examples of said amide derivatives are mentioned 1-[2-[5-(3-methoxy-4-ethoxycarbonyloxyphenyl)-2,4-pentadienoyl]-aminoethyl ]-4-benzhydroxypiperidine, 1-[2-[3-(3-methoxy-4-ethoxycarbonyloxyphenyl)-2-propenoyl]aminoethyl]-4-be nzhydroxypiperidine, 1-[3-[5-(3-methoxy-4-ethoxycarbonyloxyphenyl)-2,4-pentadienoyl]aminopropyl ]-4-benzhydrylpiperazine and the like. These amide derivatives are useful as antiallergic agents.

Abstract: A method of treating or preventing hyperlipemia by administering ethanolamine derivatives. As preferable ethanolamine derivatives are mentioned N-(9,12,15,-octadecatrienoyl)-2-aminoethyl nicotinate, N-(5,8,11,14,17-eicosapentaenoyl)-2-aminoethyl nicotinate and the like. Hyperlipemia is effectively prevented or treated by administering 300-2000 mg per day of said ethanolamine derivative for adults.

Abstract: Novel dienyl derivatives are disclosed. As examples of said diene derivative are mentioned 1-benzhydryl-4-(5-phenyl-2,4-pentadienyl)piperazine, 1-(4,4'-difluorobenzhydryl)-4-(5-phenyl-2,4-pentadienyl)piperazine, 1-benzhydryl-4-(5-(3,4,5-trimethoxyphenyl)-2,4-pentadienyl)piperazine, 1-(4,4'-difluorobenzhydryl)-4-(5-(2,4-dimethoxyphenyl)-2,4-pentadienyl)pip erazine, 1-benzhydryl-4-(5-(2,3,4-trimethoxyphenyl)-2,4-pentadienyl)piperazine, 1-(4,4'-difluorobenzhydryl)-4-(5-(2,3,4-trimethoxyphenyl)-2,4-pentadienyl) piperazine and the like. These dienyl derivatives are useful as vasodilators.

Abstract: Novel pyrazine derivatives are disclosed. The compounds possess a potent platelet aggregation-inhibiting activity and are effective for preventing diseases caused by aggregation of the platelet, for example, myocardial infarction and cerebral thromobsis. Representative examples of the pyrazine derivatives includes 2,3-bis(p-chlorophenyl)-5-methylpyrazine, 2,3-bis(p-methoxyphenyl)-5-methylpyrazine, 2,3-diphenyl-5-benzylpyrazine, 2,3-diphenyl-5-(p-methoxybenzyl)pyrazine, 2,3-bis(p-methoxyphenyl)-5-isopropylpyrazine, 2,3-bis(p-methoxyphenyl)-5-(2-thienylmethyl)pyrazine and 2,3-bis(p-methoxyphenyl)-5,6-dimethylpyrazine.The pyrazine derivatives can be generally prepared by heating a benzil derivative and a 1,2-diaminoethane derivative to produce a dihydropyrazine derivative and heating the resulting compound with sulfur at 100.degree.-180.degree. C.

Abstract: Novel nitrate derivatives are disclosed. As examples of said nitrate derivative are described N-(.beta.-hydroxyethyl)-5-(3,4,5-trimethoxyphenyl)2,4-pentadienoic acid amide nitrate, N-(.beta.-hydroxyethyl)-3,4,5-trimethoxycinnamic acid amide nitrate and the like. These nitrate derivatives are useful as vasodilators.

Abstract: Novel 2,4-pentadienoic acid derivatives are disclosed. As the examples are mentioned 3-(4-carboxy-trans, trans-1,3-butadienyl)-6-exo-(3.alpha.-hydroxy-trans-1-octenyl)-7-endo-hydr oxybicyclo[3.3.0]oct-2-ene, 3-(5-carboxy-trans, trans-2,4-pentadienyl)-6-exo-(3.alpha.-hydroxy-trans-1-octenyl)-7-endo-hyd roxybicyclo[3.3.0]oct-2-ene and the like. These compounds are useful as a platelet aggregation inhibitor, especially as a thrombosis-prophylactic agent.

Abstract: 5-Fluorouracil derivatives represented by general; formula I: ##STR1## wherein R represents an acyl group derived from an unsaturated higher fatty acid selected from the group consisting of triene higher acids, pentaene higher acids, and hexaene higher fatty acids, can be used as for inhibiting platelet aggregation and an anticancer chemotherapeutic agent. They may be mixed with a pharmaceutically acceptable carrier or a diluent to form a medicinal preparation.

Abstract: According to the invention, there are provided novel amide derivatives and 5-lipoxygenase inhibitors containing the same as an effective ingredient.The above-mentioned compounds of the invention have been demonstrated to posses 5-lipoxygenase-inhibiting activities. These compounds can inhibit the production of leucotrienes such as LTC.sub.4 and LTD.sub.4 which are allergy-inducing factors by inhibiting the activity of 5-lipoxygenase. Accordingly, the amide derivatives can be used as 5-lipoxygenase inhibitors effective for allergic asthma, allergic rhinitis and the like.

Abstract: A parenteral alimentation solution having excellent nutritional properties with preventing problems such as browning which comprises three components of a reducing sugar, amino acids and electrolytes in a specific composition and a specific amount.

Abstract: There are disclosed novel piperazine derivatives and vasodilators containing the same. The compounds are useful for controlling or preventing vascular disorders such as cerebral embolism, myocardial infarction and limb arterial obstruction. As typical compounds are mentioned 1-[5-(3,4,5-trimethoxyphenyl)-2,4-pentadienoyl]-4-(pyrrolidinocarbonylmeth yl)-piperazine, 1-[5-(3,4,5-trimethoxyphenyl)-2,4-pentadienoyl]-4-(N-isopropylaminocarbony lmethyl)-piperazine, 1-[5-(3,4,5-trimethoxyphenyl)-2,4-pentadienoyl]-4-(N,N-dimethylaminocarbon ylmethyl)piperazine and 1-[5-(3,4,5-trimethoxyphenyl)-2,4-pentadienoyl]-4-(methylaminocarbonylmeth yl)-piperazine.

Abstract: Alkanolamine derivatives and platelet aggregation inhibitors containing the same as an active ingredient are disclosed. The alkanolamine derivatives are novel compounds which possess potent platelet aggregation inhibitory activities and effective in preventing diseases such as thrombosis. As typical compounds are mentioned N-5,8,11,14,17-eicosapentaenoyl-2-aminoethanol, N-nicotinoyl-2-aminoethyl-5,8,11,14,17-eicosapentaenoate, N-ethyl-N-5,8,11,14,17-eicosapentaenoyl-2-aminoethanol, N-butyl-N-5,8,11,14,17-eicosapentaenoyl-2-aminoethanol, N-5,8,11,14,17-3-aminopropylnicotinate, (N-ethyl-N-nicotinoyl-2-aminoethyl)-5,8,11,14,17-eicosapentaenoate and the like.

Abstract: A composition for curing respiratory diseases which contains a medicine such as antibiotic, chemotherapeutic and anticancer drug for respiratory disease and lung surfactant.